A Model of a Zebrafish Avatar for Co-Clinical Trials.
chemosensitivity
equivalent dose
patient-derived xenograft
translational research
zebrafish avatar
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Mar 2020
13 Mar 2020
Historique:
received:
11
02
2020
revised:
08
03
2020
accepted:
10
03
2020
entrez:
19
3
2020
pubmed:
19
3
2020
medline:
19
3
2020
Statut:
epublish
Résumé
Animal "avatars" and co-clinical trials are being developed for possible use in personalized medicine in oncology. In a co-clinical trial, the cancer cells of the patient's tumor are xenotransplanted into the animal avatar for drug efficacy studies, and the data collected in the animal trial are used to plan the best drug treatment in the patient trial. Zebrafish have recently been proposed for implementing avatar models, however the lack of a general criterion for the chemotherapy dose conversion from humans to fish is a limitation in terms of conducting co-clinical trials. Here, we validate a simple, reliant and cost-effective avatar model based on the use of zebrafish embryos. By crossing data from safety and efficacy studies, we found a basic formula for estimating the equivalent dose for use in co-clinical trials which we validated in a clinical study enrolling 24 adult patients with solid cancers (XenoZ, NCT03668418).
Identifiants
pubmed: 32183229
pii: cancers12030677
doi: 10.3390/cancers12030677
pmc: PMC7140063
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT03668418']
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fondazione Pisa
ID : project 114/16
Références
Crit Rev Oncol Hematol. 2017 Oct;118:54-62
pubmed: 28917269
Nanomedicine. 2014 May;10(4):703-19
pubmed: 24103306
Clin Cancer Res. 2015 Mar 1;21(5):969-75
pubmed: 25573382
Zebrafish. 2009 Dec;6(4):339-46
pubmed: 20047467
Dis Model Mech. 2017 Aug 1;10(8):939-942
pubmed: 28768734
Clin Lab Med. 2016 Sep;36(3):557-73
pubmed: 27514468
BMC Cancer. 2009 Apr 28;9:128
pubmed: 19400945
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
Cell. 2015 Sep 24;163(1):39-53
pubmed: 26406370
Chin Clin Oncol. 2017 Jun;6(3):25
pubmed: 28705002
Cell Tissue Res. 2018 May;372(2):233-243
pubmed: 28924803
Adv Ther. 2016 May;33(5):747-59
pubmed: 27085323
J Clin Oncol. 2000 Jan;18(1):136-47
pubmed: 10623704
J Natl Cancer Inst. 2015 Feb 12;107(2):
pubmed: 25677039
Int J Mol Sci. 2016 Aug 22;17(8):
pubmed: 27556456
Oral Oncol. 2017 Feb;65:51-56
pubmed: 28109468
J Clin Oncol. 2014 Nov 1;32(31):3520-6
pubmed: 25287828
Interface Focus. 2013 Jun 6;3(3):20130001
pubmed: 23853708
Cancer Discov. 2014 Sep;4(9):998-1013
pubmed: 25185190
BMC Cancer. 2013 Oct 04;13:453
pubmed: 24089705
Angiogenesis. 2006;9(3):139-51
pubmed: 17051341
Nat Rev Cancer. 2017 Dec;17(12):751-765
pubmed: 29077691
Dev Dyn. 1995 Jul;203(3):253-310
pubmed: 8589427
Nat Rev Clin Oncol. 2012 Apr 17;9(6):338-50
pubmed: 22508028
Nat Rev Clin Oncol. 2015 Aug;12(8):491-8
pubmed: 25895610
Dev Dyn. 2005 Aug;233(4):1560-70
pubmed: 15968639
Cancer Lett. 2014 Mar 1;344(1):1-12
pubmed: 24157811
Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):E8234-E8243
pubmed: 28835536